# Phase I Study to Compare the Pharmacokinetics, Pharmacodynamics, and Safety Between CT-P41 and US-licensed Prolia in Healthy Male Subjects

> **NCT06037395** · PHASE1 · COMPLETED · sponsor: **Celltrion** · enrollment: 154 (actual)

## Conditions studied

- Healthy Subject

## Interventions

- **BIOLOGICAL:** CT-P41
- **BIOLOGICAL:** US-licensed Prolia

## Key facts

- **NCT ID:** NCT06037395
- **Lead sponsor:** Celltrion
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-06
- **Primary completion:** 2022-10-20
- **Final completion:** 2022-10-20
- **Target enrollment:** 154 (ACTUAL)
- **Last updated:** 2023-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06037395

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06037395, "Phase I Study to Compare the Pharmacokinetics, Pharmacodynamics, and Safety Between CT-P41 and US-licensed Prolia in Healthy Male Subjects". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06037395. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*